Anti-Myelin-Associated Glycoprotein Associated Polyneuropathy

Anti-MAG peripheral neuropathy, Anti-MAG neuropathy, Neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein

Anti-MAG associated polyneuropathy is a rare autoimmune disease where the body’s own defense system attacks the protective covering of nerves, leading to numbness, weakness, and balance problems that develop slowly over time.

Table of contents

• What Is Anti-MAG Neuropathy
• How Common Is This Condition
• Symptoms and Signs
• How It Is Diagnosed
• Treatment Options
• Living with Anti-MAG Neuropathy

What Is Anti-MAG Neuropathy

Anti-MAG associated polyneuropathy is a specific type of peripheral neuropathy, which means nerve damage affecting the body’s outer nervous system. In this condition, the person’s own immune system creates antibodies that attack cells responsible for maintaining healthy nerves. These antibodies specifically target a protein called myelin-associated glycoprotein (MAG), which is found in the protective covering around nerve fibers.^[1][3]

The disease is characterized as a distal and symmetric, mostly sensory neuropathy. This means it affects both sides of the body equally and primarily causes problems with sensation rather than movement, typically starting in the hands and feet.^[1] Anti-MAG neuropathy develops most often in the context of an IgM-type monoclonal gammopathy, which is an abnormal production of a specific type of antibody by immune cells.^[4]

The condition is often associated with “monoclonal gammopathy of undetermined significance (MGUS),” which is a potentially cancerous but usually benign condition. In some cases, it may also occur with lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia.^[3][4]

How Common Is This Condition

Anti-MAG peripheral neuropathy is considered a very rare condition. Current estimates place its prevalence at around 1 per 100,000 people in the general population.^[3] Among people who have conditions similar to chronic inflammatory demyelinating polyneuropathy (CIDP), anti-MAG neuropathy represents only about 5 percent of cases.^[3]

The disease is most commonly seen in individuals over 60 years old, with the peak age of onset occurring around 66 to 70 years.^[3] Autoantibodies against MAG are present in approximately 50 to 70 percent of people who have an IgM M-protein and display the characteristic pattern of nerve damage associated with this condition.^[5]

Symptoms and Signs

The disorder is predominantly characterized by sensory problems that develop slowly over time. People with anti-MAG neuropathy typically experience sensory loss that starts in their toes and fingers and gradually spreads. One of the most characteristic features is loss of vibration sense, which affects the ability to feel vibrations through the skin.^[3]

Common symptoms include:

• Sensory loss starting in toes and fingers
• Loss of vibration senses
• Unsteady walking (gait)
• Tremors in hands and legs
• Poor balance
• Muscle weakness

People afflicted with this condition may experience muscle weakness, sensory problems, and other difficulties with movement, usually starting in the form of a tremor of the hands or trouble walking.^[6] The clinical picture is characterized by a distal and symmetric presentation, with symptoms being predominantly sensory in nature.^[1]

How It Is Diagnosed

Diagnosis begins with a neurological examination performed by a doctor. If the examination indicates that the patient has a peripheral neuropathy, several tests are conducted to confirm anti-MAG neuropathy specifically.^[3]

Testing for a monoclonal gammopathy is performed through blood work. This is done along with electrodiagnostic testing, which includes nerve conduction studies that measure how well electrical signals travel through the nerves. These studies typically demonstrate a characteristic progressive sensory predominant mixed pattern of nerve damage, with reduced conduction velocities that are greater in the parts of nerves farther from the body’s center.^[5]

If the blood work and the EMG (electromyography) show appropriate abnormalities, blood testing specifically for anti-MAG antibody is performed. Detection of MAG IgM antibody is done using specialized laboratory tests. Higher MAG antibody levels (greater than 10,000 Buhlmann titer units) are better predictors of the characteristic pattern of nerve damage, whereas low antibody levels may be associated with a more diverse group of nerve problems.^[5]

Additional blood work may be done to exclude other causes for the patient’s condition. Some patients will have an elevated protein level in their cerebral-spinal fluid, which can be obtained through a procedure called a spinal tap.^[3] Different electrophysiological measurements have been shown to distinguish anti-MAG-associated polyneuropathy from other similar conditions.^[1]

Treatment Options

The treatment of anti-MAG neuropathy has evolved over time, with various approaches showing different levels of effectiveness. Rituximab, a monoclonal antibody that targets CD20 on B cells, is considered standard therapy for patients who have not been previously treated.^[4][9]

For patients who do not respond to rituximab or who experience relapse after initial treatment, newer options have shown promise. Bruton tyrosine kinase (BTK) inhibitors such as tirabrutinib and zanubrutinib have demonstrated effectiveness in managing this condition. These medications work by blocking specific signals in immune cells that produce the harmful antibodies.^[4][9]

Case reports have shown that tirabrutinib led to dramatic improvements in nerve damage symptoms, confirmed by nerve conduction studies, in patients who did not respond to rituximab. The medication provided excellent disease control with no apparent adverse events, and patients were able to stop other treatments like plasmapheresis (a procedure to filter antibodies from the blood) that were previously necessary.^[4]

Similarly, zanubrutinib therapy has shown mild improvement in neuropathy symptoms in patients with Waldenström macroglobulinemia and anti-MAG neuropathy. Laboratory tests demonstrated a decrease in anti-MAG antibody levels following treatment, though some patients reported increased fatigue and musculoskeletal pain.^[9]

Other treatment approaches that have been studied include various forms of immunotherapy and chemotherapy. However, response to treatment can vary among patients. In general, patients with anti-MAG neuropathy show limited treatment responses to intravenous immunoglobulin, and more aggressive immunotherapy may be needed.^[5]

It is important to note that MAG antibody levels do not necessarily correlate with disease severity or treatment responses, meaning that the amount of antibody in the blood does not always predict how well someone will respond to treatment.^[5]

Living with Anti-MAG Neuropathy

The progression of anti-MAG neuropathy is generally slower and less severe than some other similar nerve conditions. Many patients continue living relatively normal lives while managing their symptoms with simple exercises or drug therapies. Only about 10 percent of patients become severely disabled and require wheelchair use.^[3]

Research has shown that this condition can lead to significant disability and impairment of health-related quality of life and social participation, despite being reported as a slowly progressive disease. Studies examining functioning and quality of life in patients with anti-MAG neuropathy have identified important factors that affect daily living.^[11]

Walking ability, measured by the 6-minute walk distance test, has been found to be the most reliable predictor of physical quality of life. The strongest factors determining walking ability were balance (measured by the Berg balance scale) and fatigue. Pain levels and balance were also good predictors of physical well-being.^[11]

Fatigue was identified as the most reliable factor affecting mental quality of life, explaining a significant portion of mental well-being scores. These findings suggest that rehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to improve participation in social life and overall quality of life for people with anti-MAG neuropathy.^[11]

Research is ongoing to improve understanding of this condition and develop better treatments. Current studies are working to identify improved clinical measurements, biomarkers, and therapeutic approaches for anti-MAG neuropathy.^[15]